BRPI1006633A2 - bolo liofilizado, metodo para a fabricação de um bolo liofilizado e uso de bolo liofilizado - Google Patents

bolo liofilizado, metodo para a fabricação de um bolo liofilizado e uso de bolo liofilizado

Info

Publication number
BRPI1006633A2
BRPI1006633A2 BRPI1006633A BRPI1006633A BRPI1006633A2 BR PI1006633 A2 BRPI1006633 A2 BR PI1006633A2 BR PI1006633 A BRPI1006633 A BR PI1006633A BR PI1006633 A BRPI1006633 A BR PI1006633A BR PI1006633 A2 BRPI1006633 A2 BR PI1006633A2
Authority
BR
Brazil
Prior art keywords
freeze
dried cake
making
cake
dried
Prior art date
Application number
BRPI1006633A
Other languages
English (en)
Inventor
Bricout Denis
Cambourieux Helene
L Cappola Michael
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of BRPI1006633A2 publication Critical patent/BRPI1006633A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI1006633A 2009-04-03 2010-04-01 bolo liofilizado, metodo para a fabricação de um bolo liofilizado e uso de bolo liofilizado BRPI1006633A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16652909P 2009-04-03 2009-04-03
EP09305291A EP2238973A1 (en) 2009-04-07 2009-04-07 Lyophilized preparations of proteasome inhibitors
US28895509P 2009-12-22 2009-12-22
PCT/US2010/029597 WO2010114982A2 (en) 2009-04-03 2010-04-01 Lyophilization cakes of proteasome inhibitors

Publications (1)

Publication Number Publication Date
BRPI1006633A2 true BRPI1006633A2 (pt) 2019-09-24

Family

ID=41130433

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006633A BRPI1006633A2 (pt) 2009-04-03 2010-04-01 bolo liofilizado, metodo para a fabricação de um bolo liofilizado e uso de bolo liofilizado

Country Status (16)

Country Link
US (1) US8785418B2 (pt)
EP (2) EP2238973A1 (pt)
JP (1) JP5722871B2 (pt)
KR (1) KR20120016082A (pt)
CN (1) CN102387790B (pt)
AR (1) AR084663A1 (pt)
AU (1) AU2010232632C1 (pt)
BR (1) BRPI1006633A2 (pt)
CA (1) CA2757463A1 (pt)
CL (1) CL2011002460A1 (pt)
IL (1) IL215325A (pt)
MX (1) MX2011010422A (pt)
NZ (1) NZ596056A (pt)
TW (1) TWI484981B (pt)
WO (1) WO2010114982A2 (pt)
ZA (1) ZA201107852B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600786A (en) * 2009-12-22 2013-12-20 Cephalon Inc Proteasome inhibitors and processes for their preparation, purification and use
RU2529800C2 (ru) * 2010-03-18 2014-09-27 ИННОФАРМА, Инк. Стабильные составы бортезомиба
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
EP2624818B1 (en) 2010-10-05 2017-04-05 Fresenius Kabi USA, LLC Bortezomib formulations stabilised with boric acid
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN102784114B (zh) * 2011-05-14 2016-03-02 山东新时代药业有限公司 一种硼替佐米冻干粉针及其制备方法
WO2012177835A1 (en) * 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CA2784240C (en) * 2012-03-27 2014-07-08 Innopharma, Inc. Stable bortezomib formulations
EA021179B1 (ru) * 2012-06-15 2015-04-30 Ощество С Ограниченной Ответственностью "Тева" Лиофилизат соединения бороновой кислоты
WO2014072985A1 (en) * 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型,制备方法及其运用
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型,制备方法及其在硼替佐米合成中的运用
WO2014102755A1 (en) * 2012-12-31 2014-07-03 Shilpa Medicare Limited Bortezomib formulations
CN103070835B (zh) * 2013-01-31 2015-01-07 江苏奥赛康药业股份有限公司 一种含硼替佐米的冻干组合物及其制备方法
WO2014161072A1 (en) * 2013-04-02 2014-10-09 The Governing Council Of The University Of Toronto Α-boryl isocyanides, boropeptides and boron heterocycles
CN103212055B (zh) * 2013-04-19 2014-11-05 海南锦瑞制药股份有限公司 一种硼替佐米的药物组合物及其制备方法
WO2014190992A1 (en) * 2013-05-29 2014-12-04 Gea Process Engineering A/S Method of providing inline sterile freeze drying of a product in trays accommodated in a trolley, system for carrying out the method, and use of the method
CN103720666B (zh) * 2013-12-16 2015-11-25 亿腾药业(泰州)有限公司 一种注射用硼替佐米冻干制剂的制备方法
WO2016205790A2 (en) 2015-06-19 2016-12-22 Hanlin Scientific, Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
EP3310360B1 (en) * 2015-06-19 2024-03-27 Beijing Artivila BioPharma Co. Ltd. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
CN106176637A (zh) * 2016-08-24 2016-12-07 江苏豪森药业集团有限公司 硼替佐米的冻干制剂及其制备方法
AU2017382281B2 (en) * 2016-12-22 2024-07-11 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
RU2659160C1 (ru) * 2017-07-10 2018-06-28 Акционерное Общество "Фарм-Синтез" Способ получения лиофилизата бортезомиба и фармацевтическая композиция, содержащая бортезомиб в форме стабильного лиофилизованного продукта, полученная указанным способом
CN110540547A (zh) * 2018-05-28 2019-12-06 秦艳茹 一种肽硼酸酯类化合物的合成与用途
EP3824880A1 (en) * 2019-11-25 2021-05-26 Clevexel Pharma Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5835968B2 (ja) 1974-02-25 1983-08-05 帝人株式会社 サイクロデキストリン包接化合物の製造法
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
JPS5920230A (ja) 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2593809B1 (fr) 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
JPS62281855A (ja) 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン,ビタミン誘導体,またはホルモンを含有する包接化合物
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
GB8813682D0 (en) 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
JPH035438A (ja) 1989-05-31 1991-01-11 Kaken Pharmaceut Co Ltd フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
CA2013485C (en) 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
US5024997A (en) 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
JP3176716B2 (ja) * 1991-06-21 2001-06-18 武田薬品工業株式会社 溶解性が向上した難水溶性薬物組成物
FR2684875B1 (fr) 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
US5843347A (en) 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2702968B1 (fr) 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
US5866162A (en) 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6077871A (en) 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6346548B1 (en) 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
CA2435146C (en) * 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
ES2899606T3 (es) 2004-03-30 2022-03-14 Millennium Pharm Inc Síntesis de compuestos de ésteres y ácidos borónicos
EP2261236B1 (en) * 2004-12-07 2015-07-15 Onyx Therapeutics, Inc. Composition for proteasome inhibition
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
ATE475408T1 (de) * 2005-10-14 2010-08-15 Janssen Pharmaceutica Nv Formulierungen von tipifarnib zur intravenösen verabreichung
WO2008063634A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors

Also Published As

Publication number Publication date
CA2757463A1 (en) 2010-10-07
IL215325A0 (en) 2011-12-29
AU2010232632A1 (en) 2011-11-24
US8785418B2 (en) 2014-07-22
AU2010232632C1 (en) 2016-09-22
AU2010232632B2 (en) 2016-04-21
CN102387790B (zh) 2014-12-10
TW201039865A (en) 2010-11-16
JP5722871B2 (ja) 2015-05-27
CN102387790A (zh) 2012-03-21
KR20120016082A (ko) 2012-02-22
IL215325A (en) 2016-06-30
US20120035133A1 (en) 2012-02-09
ZA201107852B (en) 2012-07-25
EP2413916A2 (en) 2012-02-08
TWI484981B (zh) 2015-05-21
WO2010114982A2 (en) 2010-10-07
CL2011002460A1 (es) 2012-09-14
MX2011010422A (es) 2011-10-17
AR084663A1 (es) 2013-06-05
JP2012522795A (ja) 2012-09-27
WO2010114982A3 (en) 2011-09-01
EP2238973A1 (en) 2010-10-13
NZ596056A (en) 2012-10-26

Similar Documents

Publication Publication Date Title
BR112012001978A2 (pt) filtro e método de preparação do filtro
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI1010774A2 (pt) método de uso de particulados.
UY33094A (es) Procedimiento para la preparacion de dronedarona
BR112012000882A2 (pt) Preparação cosmética capilar e método para aplicação.
BR112012010286A2 (pt) painel transparente, método para produção de um painel transparente, e, uso de um painel transparente
BR112013006092A2 (pt) laminado, matéria-prima do laminado, método para preparação de um laminado e uso do laminado
BR112012019936A2 (pt) uso de um composto, método de preparação de um composto, método e composto
BRPI1010798A2 (pt) fechamento, aparelho de retenção, e método de uso do mesmo
BR112014016047A2 (pt) composição de compósito degradável, composição, e método de uso um compósito degradável
BR112012004807A2 (pt) vacina para pcsk9
BRPI1011331A2 (pt) objeto transparente, eletricamente aquecível extensivamente, método para produção de um objeto transparente, eletricamente aquecível extensivamente, e, uso do objeto transparente, eletricamente aquecível extensivamente
PT3686183T (pt) Fenilacetato de l-ornitina e métodos de preparação do mesmo
BRPI1014574A2 (pt) Compostos inéditos de imitadores de ligação revesa, método para fabricar os mesmos e uso destes
BRPI0907298A2 (pt) preparação solúvel em água, método para produzir uma preparação e uso de uma preparação
FI20096339L (fi) Liima-aine, menetelmä sen valmistamiseksi sekä sen käyttö
BRPI0910286A2 (pt) métodos para transformação de levedura
BRPI1006996A2 (pt) composição, método e uso
FI20095428L (fi) Komposiittivälituote, menetelmä sen muodostamiseksi ja komposiittivälituotteen käyttö
FI20095500L (fi) Tuote ja menetelmä sen valmistamiseksi
BRPI1008382A2 (pt) Extrato de oregano para vivacidade
EP2514854A4 (en) ITEM FOR TRANSPORT OF MATERIALS AT HIGH TEMPERATURE
BR112013015085A2 (pt) composição farmacêutica, método para preparar uma composição, e, uso de composição
FI20090357L (fi) Menetelmä ja järjestely
BRPI1011870A2 (pt) método para a produção de uma vidraça com reflexão reduzida, vidraça, e, uso de uma vidraça

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: CEPHALON, INC (US)

Free format text: A FIM DE ATENDER AS TRANSFERENCIAS, REQUERIDAS ATRAVES DA PETICAO NO 18130037080 DE 08/11/2013, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25B Requested transfer of rights rejected

Owner name: CEPHALON, INC (US)

Free format text: INDEFERIDO(S) O(S) PEDIDO(S) DE TRANSFERENCIA(S) CONTIDO(S) NA PETICAO 018130037080 DE 08/11/2013 EM VIRTUDE DO DESPACHO PUBLICADO NA RPI NO 2559 DE 21/01/2020.